Here, we aim to investigate the interactions between the usage of semaglutide (e.g., Ozempic, GLP-1-RA), empagliflozin (e.g., Jardiance, SGLT-2i), and the gut microbiome
Profiling the proximal proteome of the activated -opioid receptor
We focused on mitochondrial genes between wild-type and hepsin / mice under normal saline conditions and at 1 and 2 h post-APAP treatment (Figure S9)

References PMC Once-Weekly Semaglutide for Weight Management: A Clinical Review Comprehensive review of Semaglutides mechanism, efficacy, and safety in weight management (clinical data, half-life, GLP-1 receptor activation, weekly dosing) NCBI Bookshelf Semaglutide (StatPearls) Comprehensive pharmacology, clinical uses, dosing strategies, adverse effects, and contraindications for Semaglutide Mayo Clinic Semaglutide (Subcutaneous Route) Clinical guidance on Semaglutide administration, side effects, dosing, and patient information including weekly protocol PMC Semaglutide 2.4 mg for Weight Loss: Clinical Evidence Evidence-based review of Semaglutide 2.4 mg weekly maintenance dosing and clinical outcomes in obesity treatment PubMed Cardiovascular Outcomes with Semaglutide Long-term cardiovascular safety and benefits observed in Semaglutide clinical trials Journal of the Royal Society Interface (2017) Peer-reviewed review of formulation, temperature, agitation, lyophilization, and other factors that affect peptide stability
